MedWatch

Analyst believes in continued progress for Ambu

When Ambu reveals its Q2 financial report on Wednesday morning, Sydbank analyst Søren Løntoft Hansen expects to see continued strong growth for single-use endoscopes.

Photo: Sydbank/PR

Ambu has had wind in its sails when it comes to the sale of single-use endoscopes, which may very well continue into the second quarter of the financial year 2020/2021.

However, the growth for the company's visualization business leg is hard to compare to the second quarter last year, Søren Løntoft Hansen, senior equity analyst at Sydbank warns.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs